Curcumin inhibits hERG potassium channels in vitro

Toxicology Letters

Volumn 208, Issue 2, 2012, Pages 192-196

  Hu, Chao Wei ^a   Sheng, Yue ^a   Zhang, Qin ^a   Liu, Hui Bin ^a   Xie, Xin ^a   Ma, Wen Chao ^a   Huo, Rong ^a   Dong, De Li ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Curcumin; HERG; Potassium channel

Indexed keywords

CURCUMIN; POTASSIUM CHANNEL HERG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARDIOVASCULAR EFFECT; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ELECTROCARDIOGRAM; IC 50; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; PATCH CLAMP; POTASSIUM TRANSPORT; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; CELL SURVIVAL; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HEART; HEK293 CELLS; HUMANS; MALE; PATCH-CLAMP TECHNIQUES; RABBITS;

EID: 83455263784     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.11.005     Document Type: Article

References (18)

1. Aggarwal B.B., Sundaram C., Malani N., Ichikawa H. Curcumin: the Indian solid gold. Adv. Exp. Med. Biol. 2007, 595:1-75.
2. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol. Pharmacol. 2007, 4:807-818.
3. + channels: a potential mechanism of HIV infection induced LQTs. J. Mol. Cell. Cardiol. 2011, 51:876-880.
4. - channel activity. J. Biol. Chem. 2005, 280:5221-5226.
5. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai M.K., Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., Hsieh C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21:2895-2900.
6. Dong D.L., Wang Q.H., Yue P., Jiao J.D., Gu R.M., Yang B.F. Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur. J. Pharmacol. 2006, 536:78-84.
7. + channels and stimulates cortisol secretion from adrenocortical cells. Biochem. Biophys. Res. Commun. 2008, 370:623-628.
8. Enyeart J.A., Liu H., Enyeart J.J. Curcumin inhibits ACTH- and angiotensin II-stimulated cortisol secretion and Ca(v)3.2 current. J. Nat. Prod. 2009, 72:1533-1537.
9. Farhangkhoee H., Khan Z.A., Chen S., Chakrabarti S. Differential effects of curcumin on vasoactive factors in the diabetic rat heart. Nutr. Metab. (Lond.) 2006, 3:27.
10. Lao C.D., Ruffin M.T., Normolle D., Heath D.D., Murray S.I., Bailey J.M., Boggs M.E., Crowell J., Rock C.L., Brenner D.E. Dose escalation of a curcuminoid formulation. BMC. Complement. Altern. Med. 2006, 17:6-10.
11. Liu H., Danthi S.J., Enyeart J.J. Curcumin potently blocks Kv1.4 potassium channels. Biochem. Biophys. Res. Commun. 2006, 344:1161-1165.
12. Morimoto T., Sunagawa Y., Kawamura T., Takaya T., Wada H., Nagasawa A., Komeda M., Fujita M., Shimatsu A., Kita T., Hasegawa K. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest. 2008, 118:868-878.
13. Nirmala C., Puvanakrishnan R. Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol. Cell. Biochem. 1996, 159:85-93.
14. Olszanecki R., Jawien J., Gajda M., Mateuszuk L., Gebska A., Korabiowska M., Chlopicki S., Korbut R. Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J. Physiol. Pharmacol. 2005, 56:627-635.
15. + channels by curcumin in Jurkat-T cells. J. Pharmacol. Sci. 2011, 115:144-154.
16. Singh S. From exotic spice to modern drug?. Cell 2007, 130:765-768.
17. + channels: friend and foe. Trends. Pharmacol. Sci. 2001, 22:240-246.
18. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br. J. Pharmacol. 1998, 124:425-427.